Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 6Gastrointestinal 4Other solid neoplasm 3Breast 2Thoracic 1

Conditions

Colorectal Neoplasms 3Gastrointestinal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × tivozanib × Gastrointestinal × Clear all
NCT03970616 2023-07-12

DEDUCTIVE

AVEO Pharmaceuticals, Inc.

Phase 1/2 Terminated
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01478594 2015-07-08

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

AVEO Pharmaceuticals, Inc.

Phase 2 Completed
265 enrolled 34 charts
Gastrointestinal

Colorectal Neoplasms

NCT01306630 2014-01-27

A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
24 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00660153 2012-08-28

Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
30 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡